idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Grafik: idw-Logo

idw - Informationsdienst
Wissenschaft

Science Video Project
idw-Abo

idw-News App:

AppStore

Google Play Store



Instance:
Share on: 
01/21/2008 11:20

'Nature' - new findings in pain research published

Renata Cosby Corporate Communications
Eidgenössische Technische Hochschule Zürich (ETH Zürich)

    For people suffering from chronic pain, the spinal cord, which acts as a kind of filter for pain signals, is impaired. Led by ETH Zurich Professor Hanns Ulrich Zeilhofer, researchers have now found a way to restore it. Their results have been published in 'Nature'.

    Our bodies sense painful stimuli through certain receptors located in the skin, in joints and many internal organs. Specialized nerve fibers relay these signals coming from the periphery to the brain, where pain becomes conscious. "The spinal cord is placed between these structures as kind of a pain filter", says Hanns Ulrich Zeilhofer, Professor at the Institute of Pharmaceutical Sciences at ETH Zurich and at the Institute of Pharmacology and Toxicology of the University of Zurich.

    That filter assures that pain is not evoked by everyday stimuli like light touch. This is accomplished by inhibitory nerve cells located in the spinal dorsal horn that release the messenger molecule ?-amino butyric acid (GABA) at specialized contacts between neighboring nerve cells, so-called synapses. GABA then activates chloride channels on those neighboring cells which relay the pain signals to the brain.

    Activating pain inhibiting factors

    In patients with chronic inflammatory diseases, such as rheumatoid arthritis or after nerve damage, for example following injuries, the pain inhibiting action of GABA becomes severely compromised. Pain signals are then conducted to the brain nearly unfiltered. Benzodiazepines, such as the sedative drug Valium®, which enhance the action of GABA, alleviate chronic pain when they are applied directly to the spinal cord via an injection into the spinal canal. In practice, however, such injections can only be done in very selected cases. More often benzodiazepines are administered systemically, such as with tablets. In this instance, the benzodiazepines not only act in the spinal cord but also in the brain where they can have undesired, sometimes deleterious, effects on pain patients. The drugs cause sedation, impair memory, and can even lead to addiction. In addition, during prolonged treatment their effect often fades with time. Classic benzodiazepines should therefore be avoided in chronic pain patients.

    GABAA receptors as pain targets

    It had been acknowledged for some time that GABA serves important functions in pain control. That benzodiazepines act on at least four different subtypes of GABA receptors was also known. Nonetheless, these receptors were largely neglected as potential targets for pain treatment.

    The research team led by Ulrich Zeilhofer used genetically altered mice in ex-periments to target the GABA receptors that control spinal pain relay. They first induced a slight inflammation in one hind paw or irritated the sciatic nerve to induce pain. A few days later the mice received an injection of a benzodiazepine close to the spinal cord. Experiments with the mice allowed the researchers to identify two subtypes of GABAA receptors which mediate spinal pain control.

    A challenge for drug design

    For experiments with animals, drugs with the proposed receptor specificity are already available. Such experiments have confirmed that the pharmacological enhancement of spinal GABA receptor function inhibits the relay of pain signals to the brain. Further studies have also shown that these compounds did not lose their analgesic effects during prolonged treatment and did not lead to addiction.

    Successful design of a drug that targets only those two subtypes of GABA re-ceptors would be a big step forward in pain therapy. Chronic pain could be treated specifically and with fewer side effects. "The challenge is now for phar-maceutical companies to develop drugs that specifically target these receptors in humans", says Zeilhofer.

    A diagram can be downloaded from the following link: http://www.cc.ethz.ch/media/picturelibrary/news/gaba


    More information:

    http://Prof. Hanns Ulrich Zeilhofer
    http://Institute for Pharmaceutical Sciences (ETH Zürich)
    http://Institute for Pharmacology and Toxicology (University of Zürich)
    http://Tel : +41 (0) 44 635 59 12
    http://Email :hansze@ethz.ch


    Images

    Criteria of this press release:
    Biology, Information technology, Materials sciences, Medicine, Nutrition / healthcare / nursing
    transregional, national
    Research results
    English


     

    Help

    Search / advanced search of the idw archives
    Combination of search terms

    You can combine search terms with and, or and/or not, e.g. Philo not logy.

    Brackets

    You can use brackets to separate combinations from each other, e.g. (Philo not logy) or (Psycho and logy).

    Phrases

    Coherent groups of words will be located as complete phrases if you put them into quotation marks, e.g. “Federal Republic of Germany”.

    Selection criteria

    You can also use the advanced search without entering search terms. It will then follow the criteria you have selected (e.g. country or subject area).

    If you have not selected any criteria in a given category, the entire category will be searched (e.g. all subject areas or all countries).